Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - License Agreements - Additional Information (Details)

v3.21.1
Commitments and Contingencies - License Agreements - Additional Information (Details) - TMRC - USD ($)
1 Months Ended 3 Months Ended
Sep. 30, 2016
May 31, 2016
Sep. 30, 2015
Mar. 31, 2021
Mar. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Up-front license fee     $ 1,000,000.0    
Payment of up-front license fee   $ 500,000 500,000    
Payments per indication due upon the successful achievement of clinical and regulatory milestones     $ 13,000,000.0    
Payments made upon achievement of development milestone $ 1,000,000.0        
Fees incurred under supply management agreement       $ 0 $ 300,000